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Abstract
The cytoplasmic domain of lentiviral Envelopes (EnvCD) ensures Env incorporation into nascent virions and regulates
Env trafficking to and from the plasma membrane. It has also been reported to promote transcription from the viral
LTR both directly and indirectly. Noticeably, the HIV-1 and SIVmac239 EnvCDs were described to trigger nuclear
translocation of NF-κB (Postler, Cell Host Microbes 2012). Given the paramount importance of identifying viral
and host factors regulating HIV transcription, cellular signaling pathways and latency, and given that viral replication
capacity is dependent on Env, we asked whether HIV EnvCDs from different HIV-1 subtypes differently modulated
NF-κB. To that aim, we evaluated the ability of primary HIV-1 Envs from subtypes B and C to activate the NF-κB pathway.
Primary subtype B and C Envs all failed to activate the NF-κB pathway. In contrast, when the EnvCD of HIV-1 Envs was
fused to the the CD8-α chain, it induced ~ 10-fold increase in NF-κB induction, and this increase was much stronger with
a truncated form of the HIV EnvCD lacking the 76 C-terminal residues and containing the proposed TAK-1 binding
domain. Our results indicate that the HIV-1 EnvCD is unlikely to trigger the NF-κB pathway in its native trimeric form.
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The cytoplasmic domain (CD) of lentiviral envelopes
(Env) is unusually long (~ 150 residues) compared to
other retroviruses (< 50 residues) [1] and reviewed in
[2–5]. It comprises a disordered sequence with a tyro-
sine-based internalization signal immediately downstream
of the membrane-spanning-domain (MSD), an immunodo-
minant epitope and three amphipathic α-helices (lentiviral
lytic peptides, LLP-2, LLP-3 and LLP-1). Despite consider-
able sequence variation, the physicochemical and
structural properties of peptides spanning the LLP re-
gions are believed to be conserved across HIV types
and subtypes [6].
The EnvCD ensures Env incorporation into the nas-
cent virion [7–16]. It also regulates Env trafficking to
and from the plasma membrane [17, 18] through the
endolysosomal and Trans-Golgi-Network (TGN) by
interacting with multiple cellular factors, including
AP1–3, TIP47, Rab9, Rab11A/FIP1C and retromer com-
ponents Vps26 and Vps35 [19–25]. Different groups
have reported that the EnvCD could also enhance viral
transcription, by relieving RhoA-mediated transcrip-
tional inhibition through the interaction of LLP-3 with
p155-RhoGEF [26, 27] and by affecting the stability of
the precursor of luman, a repressor of Tat-mediated HIV
transcription [28]. The HIV-1 and SIVmac239 EnvCDs
were also reported to induce the nuclear translocation of
NF-κB p65/RelA [29]. For HIV-1, residues 759–770,
encompassing the Y768HRL motif at the N-terminus of
LLP-2 interact with TAK-1, leading to phosphorylation
of IκB [29].
In vitro, differences in viral replication capacity across
subtypes map to the viral Env [30–34]. Because NF-κB
activates T-lymphocytes and the viral promoter LTR
contains NF-κB binding sites [35], we asked whether pri-
mary HIV-1 Envs from subtypes B and C differently trig-
ger the NF-κB pathway.
To evaluate NF-κB induction by different primary
HIV-1 Envs, HEK293T cells were cotransfected with a
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NF-κB-Firefly-Luciferase reporter plasmid and a panel of
13 HIV-1 full-length Envs cloned in pCDNA3.1: we used
HIV-1 EnvNL4.3 [36], EnvNLAD8 [37], EnvHXB2, subtype B
[38] and subtype C [39, 40] Envs. EnvNL4.3 harboring a
STOP codon at position 710 (EnvΔCD) was used as
negative control. All vectors express the two Rev exons.
Transfection efficiency was assessed by Flow Cytometry
and confirmed protein expression 37 and 48 h post-
transfection, with a decrease by 48 h post-transfection
(Additional file 1: Figure S1A), probably reflecting Env-
induced cell death. To normalize for transfection effi-
ciency, a plasmid expressing CMV-Renilla-Luciferase
(Promega pGL4.74 hRLuc) was included in all experi-
ments. NF-κB-Luciferase induction by each of the viral
Envs was normalized using the corresponding Renilla-
Luciferase signal, and calculated as the fold-change rela-
tive to the empty vector (mock), as in [29]. As shown in
Fig. 1a, TNF-α (Sigma) readily induced a ~ 2 log increase
in NF-κB-Luciferase, validating the system. However,
neither of the HIV-1 Envs triggered NF-κB activity (p >
0.05, Kruskal-Wallis test): NF-κB-Luciferase induction
ranged from 0.79 to 1.5 for subtype B Envs and from
0.36 to 1.16 for subtype C Envs 37 h post-transfection
and from 0.36 to 1.04 for subtype B Envs and 0.31 to
0.80 for subtype C Envs 48 h post-transfection. Varia-
tions in NF-κB-Luciferase (Fig. 1a) did not recapitulate
Env expression levels (Additional file 1: Figure S1A).
When NF-κB-Luciferase induction was further normal-
ized to Env expression levels (MFI) to account for
variability in Env expression levels, NF-κB-Luciferase
triggered by the viral Envs never exceeded the levels in-
duced by the mock control (p > 0.05, Kruskal-Wallis test)
(Additional file 2: Figure S2A), reflecting basal cell acti-
vation levels upon transfection and confirming that na-
tive Envs do not trigger NF-κB. Limiting serum in
HEK293T cell cultures (1% Fetal Bovine Serum) to en-
sure minimal basal activation did not change NF-κB in-
duction (not shown). Of note, while the HIV-1 Env
ectodomain has been reported to trigger NF-κB and
apoptosis [41–43], this phenomenon requires CD4 and
CXCR4 or a co-receptor. Here we investigated NF-κB-
induction in cells that do not express the viral receptor
CD4, excluding a similar phenomenon. The capacity of
the HIV-1 Envs to induce transcription from the LTR
was then assessed by transfecting TZM-bl cells with the
same Env expression vectors. TZM-bl cells are CD4+
CXCR4+ HeLa-derived cells expressing the Firefly Lucif-
erase and the β-galactosidase genes under the control of
the viral promoter LTR. Tat-containing Env expression
vectors (EnvNL4.3 + Tat, EnvNLAD8 + Tat) were used as posi-
tive controls and the CMV-Renilla-Luciferase vector was
included for normalization. LTR-driven transcription
was induced by the Tat-containing vectors, as expected,
but not by the Env expression vectors, ranging from 0.25
to 1.51 and from 0.30 to 1.26 for subtype B and C Envs
respectively (p > 0.05, Kruskal-Wallis test) (Fig. 1b).
One major difference between our experimental set-up
and that of Postler et al. [29] lies in the use of Env ex-
pression vectors versus CD8-EnvCD chimeras, respect-
ively. To verify the impact of the ectodomain on the
ability of the EnvCD to trigger the NF-κB pathway, we
cotransfected HEK293T cells with the NF-κB-Luciferase
reporter and a construct containing the EnvCD of HXB2
(residues 707–756) fused to the extracellular and trans-
membrane domains of the CD8-α chain (residues 1–
211) [20], a kind gift from C Berlioz-Torrent. A CD8-α
construct bearing a STOP codon downstream of the
transmembrane domain (CD8STOP) was used as a nega-
tive control [20]. The CMV-Renilla-Luciferase vector
was included for normalization and the fold-change in
NF-κB-Luciferase induction was compared (Kruskal-
Wallis test). As expected, the CD8-EnvCDHXB2 chimera
induced a ~ 10-fold increase in NF-κB-dependent-Lucif-
erase expression relative to the CD8STOP construct 37 h
(p < 0.001) and 48 h (p < 0.01) post-transfection (Fig. 2a),
in agreement with the findings of Postler et al. using a
similar chimera [29]. Using a CD8-EnvCD chimera
truncated just downstream of the Y768HRL motif, CD8-
EnvCDHXB2–780 (residues 707–780 of HIV-1 EnvCDHXB2),
NF-κB-Luciferase activity was ~ 16-fold and ~ 40-fold
higher relative to CD8STOP 37 and 48 h post-transfection,
respectively (p < 0.001) (Fig. 2a), while a CD8-EnvCD
chimera truncated just upstream of the motif of inter-
est, CD8-EnvCDHXB2–760 (residues 707–760 of HIV-1
EnvCDHXB2) did not activate the NF-κB pathway (Fig. 2a),
again recapitulating the results of Postler et al. using a
CD8-EnvCD construct lacking the 74 C-terminal residues
[29]. When NF-κB induction was further normalized to
CD8-EnvCD expression levels, CD8-CDHXB2, CD8-
EnvCD780 and CD8-SIVmac239 maintained the capacity to
activate NF-κB compared to the CD8STOP construct (Add-
itional file 2: Figure S2B). Taken together, these results
show that the HIV-1 EnvCD triggers the NF-κB pathway
only when expressed downstream of CD8-α, but not in its
wild-type form downstream of the isogenic Env ectodo-
main. We then verified the intracellular localization of the
Env-based and CD8-based constructs. As shown in Fig.
2b, EnvNL4.3 and EnvHXB2 colocalized nicely with CD8-
EnvCDHXB2 and EnvΔCD colocalized with CD8STOP, argu-
ing against the possibility that different intracellular
localization accounts for this dichotomy. We also evalu-
ated the ability of CD8-α-based chimeras fused to the
EnvCDs of SIVmac239, MLV and HTLV-1 fused to the
CD8-α chain [20] to trigger NF-κB. The CD8-
EnvCDSIVmac239 induced a ~ 26-fold (p < 0.05) and 36-fold
(p < 0.01) increase in NF-κB-Luciferase 37 and 48 h post-
transfection, respectively, compared to CD8STOP (Fig. 2a).
The short EnvCDs of MLV and HTLV had no impact on
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NF-κB activity (p > 0.05) (Fig. 2a), probably because they
lack LLP domains. NF-κB induction by CD8-EnvCDHXB2
and CD8-EnvCDHXB2–780 was higher 48 h post-
transfection than 37 h post-transfection, while NF-κB
induction by CD8-EnvCDSIVmac239 was weaker 48 h post-
transfection, probably reflecting EnvCDSIVmac239 toxicity.
Given that T lymphocyte activation is a prerequisite to
HIV replication and that the viral promoter LTR con-
tains NF-κB binding sites, identifying the factors that do
promote viral transcription and induce apoptosis in a
physiological setting is of major importance. It has been
proposed that together with Nef, the EnvCD could pro-
vide CD4+ T-lymphocytes the two independent triggers
necessary for cell activation and viral replication in vivo.
Our results clearly argue against the possibility that the
HIV-1 EnvCD might trigger the NF-κB pathway during
HIV-1 infection. One possible explanation to the differ-
ences observed using CD8-EnvCD chimeras and full
length HIV-1 Envs is that differences in conformational
dynamics dictate the ability of the HIV-1 EnvCD to trig-
ger the NF-κB pathway. Determinants involved in NF-
κB induction might remain cryptic in the trimeric native
form of Env while becoming exposed in the context of
CD8-EnvCD chimeras. The N-terminal domain of the
constructs (Env-ectodomain or CD8-α) may affect the
conformation of the EnvCD. The reverse has been
b
a
Fig. 1 The HIV-1 and SIV CDs do not trigger NF-κB activation. a
Induction of NF-κB by a panel of HIV-1 subtype B and C Envs. 1.2 ×
105 HEK293T cells were cotransfected in duplicate wells with 500 ng
of pcDNA-Env expressing vector, 200 ng of NF-κB-Firefly-Luciferase
vector and 50 ng of pGL4.74-Renilla-Luciferase for normalization using
the Calcium Phosphate precipitation method. We used a panel of full-
length Envs cloned in pCDNA3.1: Env of pNL4.3, Env of pNLAD8, 5
primary subtype B Envs (EnvSVPB5, EnvSVPB11, EnvSVPB12, EnvSVPB18,
EnvSVPB8), 5 primary subtype C Envs (EnvSVPC3, EnvSVPC7, EnvSVPC10,
EnvSVPC13, EnvSVPC17) and EnvΔCD as negative control. All Env
vectors express the two Rev exons. As a positive control, NF-κB
was triggered with 100 ng/ml TNF-α 31 or 42 h post-transfection. After
37 and 48 h, Firefly- and Renilla-Luciferase were measured in cell
lysates using the Dual-Glo Luciferase kit (Promega) and the Fire-
fly-Luciferase signal was normalized using the Renilla-Luciferase.
Results are expressed as Fold-Change in NF-κB induction with respect
to the empty pcDNA3.1 vector (mock). The mean of at least two
independent experiments is reported. Error bars represent standard
error. b Induction of transcription from the viral LTR by HIV-1 subtype B
and C Envs. 8 × 104 TZM-bl cells were cotransfected with 1 μg of
pcDNA-Env expressing vector and 100 ng pGL4.74-Renilla-Luciferase in
duplicate wells. LTR-driven transcription (Firefly-Luciferase) was assessed
in cell lysates after 48 h (no signal was detected 37 h post-transfection)
and normalized using the Renilla-Luciferase. As a positive control, Env
expression vectors containing Tat were used. The empty pcDNA3.1
vector (mock) was used for standardization. The mean of three
independent experiments is reported. Error bars represent standard
error. Statistical analyses for a and b were performed with GraphPad
Prism (version 5). NF-κB induction (a) and LTR activation (b) were
compared using a Kruskal-Wallis test followed by a Dunn’s post-test
and differences were considered significant if p < 0.05
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reported in that truncations of the HIV-1 or SIVmac239
EnvCDs affect the conformation of the corresponding
extracellular domain and its susceptibility to neutralization
[44, 45]. The levels of Env oligomerization may further
modify the determinants of Env which are exposed. In the
CD8-EnvCD chimeras, the EnvCD is most likely mono- or
dimeric given that CD8 is dimeric [46]. In the native Env,
the EnvCD is mainly trimeric. These possibilities are in line
with the observation that truncated forms of the EnvCD
are more potent NF-κB pathway activators than the full-
length Env. While CD8-α-based chimeras and truncated
proteins are powerful tools to dissect the biochemical prop-
erties and molecular interactions of retroviral EnvCDs, they
have limitations, including potential conformational dis-
crepancies with the native protein, as this study documents,
and the fact that truncated EnvCDs are counter-selected in
vivo for Env incorporation is impaired [47]. Further studies
will be needed to fully appreciate the structure and func-
tions of the HIV-1 EnvCD.
Conclusions
In conclusion, the EnvCD of HIV-1 seems to trigger NF-
κB when expressed downstream of CD8-α, particularly
when truncated forms of the EnvCD are used, but this
effect does not extend to the native Env, arguing against
the likelihood that the HIV EnvCD activates this
b
a
Fig. 2 The EnvCD activates NF-κB when fused to the CD8-α chain.
a Comparison of the ability of native Env and CD8-EnvCD chimeras
to activate NF-κB. 1.2 × 105 HEK293T cells were cotransfected with
200 ng of NF-κB-Firefly-Luciferase vector, 50 ng of pGL4-Renilla-
Luciferase and 500 ng of pcDNA-Env expressing vectors (EnvHXB2,
EnvNL4.3, EnvNLAD8, EnvΔCD) or the following CD8-EnvCD chimeric
constructs: CD8-EnvCDHXB2 (residues 707–856 of EnvHXB2), CD8STOP,
CD8-EnvCDHXB2Δ3 (residues 707–760 of EnvHXB2), CD8-EnvCDHXB2Δ4
(residues 707–780 of CDHXB2), CD8-EnvCDSIVmac239 (residues 716–879
of EnvSIVmac239), CD8-EnvCDMLV (residues 640–665 of EnvMLV) and
CD8-EnvCDHTLV-I (residues 466–488 of EnvHTLV-I). Transfections were
performed in duplicate wells. Firefly and Renilla-Luciferase activities
were recorded 37 and 48 h post-transfection. The Firefly-Luciferase
signal was normalized to the Renilla-Luciferase signal. The empty
pcDNA3.1 vector was used as negative control (mock) and was used
for standardization. The mean of seven independent experiments is
reported. Error bars represent standard error. NF-κB activation by
different constructs was compared by a Kruskal-Wallis test followed
by a Dunn’s post-test using Graph Pad Prism version 5.0 and differences
were considered significant if p < 0.05. b Intracellular localization of
EnvNL43, EnvHXB2 and CD8-EnvCD. 1.2 × 105 HEK293T cells were
cotransfected with 200 ng of EnvNL4.3 or EnvHXB2 and CD8-EnvCD or
with EnvΔCD and CD8STOP. After 48 h, cells were washed and fixed
with cold absolute ethanol and stained with a polyclonal goat α-Env
antibody (Abcam ab53937) and Rabbit anti-CD8α antibody (H-160,
Santa Cruz), then sequentially incubated with donkey anti-goat
IgG then goat anti-mouse and anti-Rabbit IgG secondary antibodies
coupled to Alexa Fluor 488 and Alexa Fluor 568 (Invitrogen). Images
were captured with a Zeiss LSM510 META confocal laser scanning
microscope (Jena, Germany) equipped with a 63× Plan-NeoFluar oil
immersion objective (numerical aperture 1.3)
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pathway in its native form. The results reported in this
study confirm the crucial role of the native trimeric
structure of the HIV-1 Env protein and illustrate the
need to interpret data obtained with chimeric constructs
with the highest caution, first ensuring they extend to
native proteins. Given that the viral Env is the target of
neutralizing antibodies and given the chief role of
cellular activation in the pathogenesis of HIV-AIDS, ac-
curately identifying epitopes with potential biological
functions is of major importance for the understanding
of HIV pathology and for the design of protective vac-
cine and viral reservoir eradication strategies.
Additional files
Additional file 1: Figure S1. Expression of Env and CD8-EnvCD 37 and
48 h post-transfection by Flow Cytometry. A. Expression of subtype B and
C Env in HEK293T cells. 1.2 × 105 HEK293T cells in duplicate wells were
cotransfected in the same conditions as in Fig. 1a with all Env expression
vectors and the Luciferase expression vectors. The empty pcDNA3.1 vector
was used as negative control (mock). Duplicate wells were pooled and Env
expression was measured by flow cytometry 37 and 48 h post transfection
using a 1:1 mixture of human anti-gp120 antibodies PGT121 + F105 (AIDS
Research and Reagent program) and an APC-labelled mouse anti-human
IgG secondary antibody (Lifetech A21445). Analyses were performed using
FlowJo v10. The mean MFI of at least 3 independent experiments are
reported. Error bars represent standard deviation. B. Expression of
reference Env and CD8-EnvCD chimeras in HEK293T cells. 1.2 × 105
HEK293T cells in duplicate wells were cotransfected in the same conditions
as in Fig. 2a with Env and CD8-EnvCD expression vectors and the luciferase
expressing vectors. The empty pcDNA3.1 vector was used as negative
control (mock). Duplicate wells were pooled and cells were stained
either with the same 1:1 mixture of human anti-gp120 antibodies PGT121 +
F105 and an APC-labelled mouse anti-human IgG secondary antibody or
with a 510-labelled mouse anti-human CD8 antibody (Biolegend #301048).
Analyses were performed using FlowJo v10. The mean MFI of at least 3
independent experiments are reported. Error bars represent standard
deviation. (PDF 302 kb)
Additional file 2: Figure S2. NF-κB induction relative to Env and CD8-
EnvCD expression levels. A. NF-κB induction by subtype B and subtype C
Envs relative to Env expression levels. NF-κB induction measured in HEK
cells co-transfected with the subtype B or subtype C Envs, NF-κB-Luciferase
and CMV-Renilla-Luciferase vectors (Fig. 1a and b) was normalized to Env
expression levels (MFI, Additional file 1: Figure S1A) to account for
differences in Env expression vectors. B. NF-κB induction by CD8-EnvCD relative
to expression levels. NF-κB induction measured in HEK cells co-transfected with
the CD8-EnvCD constructs, NF-κB-Luciferase and CMV-Renilla-Luciferase vectors
(Fig. 2a and b) was normalized to CD8-EnvCD expression levels (MFI,
Additional file 1: Figure S1B) to account for differences in expression
vectors. It is noteworthy that this second normalization round is subject
to differences in antibody affinity for Env, in Env expression kinetics and
cycling dynamics, as well as in Env-induced cytotoxicity. This is particularly
the case for the subtype B and C primary Envs, while CD8-EnvCD expression
levels are less subject to differences in antibody affinity. (PDF 308 kb)
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